Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03426891
Title Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

high grade glioma

gliosarcoma

glioblastoma

Therapies

Pembrolizumab + Temozolomide + Vorinostat

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.